PMID- 22316499
OWN - NLM
STAT- MEDLINE
DCOM- 20120912
LR  - 20220317
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 134
IP  - 2
DP  - 2012 May
TI  - Implications of central immune signaling caused by drugs of abuse: mechanisms, 
      mediators and new therapeutic approaches for prediction and treatment of drug 
      dependence.
PG  - 219-45
LID - 10.1016/j.pharmthera.2012.01.008 [doi]
AB  - In the past two decades a trickle of manuscripts examining the non-neuronal 
      central nervous system immune consequences of the drugs of abuse has now swollen 
      to a significant body of work. Initially, these studies reported associative 
      evidence of central nervous system proinflammation resulting from exposure to the 
      drugs of abuse demonstrating key implications for neurotoxicity and disease 
      progression associated with, for example, HIV infection. However, more recently 
      this drug-induced activation of central immune signaling is now understood to 
      contribute substantially to the pharmacodynamic actions of the drugs of abuse, by 
      enhancing the engagement of classical mesolimbic dopamine reward pathways and 
      withdrawal centers. This review will highlight the key in vivo animal, human, 
      biological and molecular evidence of these central immune signaling actions of 
      opioids, alcohol, cocaine, methamphetamine, and 3,4-methylenedioxymethamphetamine 
      (MDMA). Excitingly, this new appreciation of central immune signaling activity of 
      drugs of abuse provides novel therapeutic interventions and opportunities to 
      identify 'at risk' individuals through the use of immunogenetics. Discussion will 
      also cover the evidence of modulation of this signaling by existing clinical and 
      pre-clinical drug candidates, and novel pharmacological targets. Finally, 
      following examination of the breadth of central immune signaling actions of the 
      drugs of abuse highlighted here, the current known common immune signaling 
      components will be outlined and their impact on established addiction 
      neurocircuitry discussed, thereby synthesizing a common neuroimmune hypothesis of 
      addiction.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Coller, Janet K
AU  - Coller JK
AD  - Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, 
      South Australia 5005, Australia. janet.coller@adelaide.edu.au
FAU - Hutchinson, Mark R
AU  - Hutchinson MR
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120201
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
SB  - IM
MH  - Animals
MH  - Central Nervous System/drug effects/immunology
MH  - Humans
MH  - Immune System/drug effects/immunology
MH  - Neuroimmunomodulation/drug effects/immunology
MH  - Signal Transduction
MH  - Substance-Related Disorders/*drug therapy/*immunology
EDAT- 2012/02/10 06:00
MHDA- 2012/09/13 06:00
CRDT- 2012/02/10 06:00
PHST- 2012/01/16 00:00 [received]
PHST- 2012/01/17 00:00 [accepted]
PHST- 2012/02/10 06:00 [entrez]
PHST- 2012/02/10 06:00 [pubmed]
PHST- 2012/09/13 06:00 [medline]
AID - S0163-7258(12)00028-9 [pii]
AID - 10.1016/j.pharmthera.2012.01.008 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2012 May;134(2):219-45. doi: 10.1016/j.pharmthera.2012.01.008. 
      Epub 2012 Feb 1.